reports
Press release Biocartis Group NV: Disclosure of transparency notificat...
Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings) BIOCARTIS GROUP NV (Euronext Brussels: BCART) PRESS RELEASE - REGULATED INFORMATION - 10 January 2024, 23:00 CET Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings) 1. Summary of notice BIOCARTIS GROUP NV received a transparency notification on January 5, 2024, of which an amended version was received on January 8, 2024, showing that...
Press release Biocartis Group NV: Disclosure of transparency notificat...
Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings) BIOCARTIS GROUP NV (Euronext Brussels: BCART) PRESS RELEASE - REGULATED INFORMATION - 10 January 2024, 23:00 CET Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings) 1. Summary of notice BIOCARTIS GROUP NV received a transparency notification on January 5, 2024, showing that JPMorgan Chase & Co., with registered office a...
Press release Biocartis Holdings Inc.: Recapitalization completed and ...
Press release Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion PRESS RELEASE - 22 November 2023, 10:00 CET BIOCARTIS HOLDINGS INC. RECAPITALIZATION COMPLETED AND PRODUCT PORTFOLIO EXPANSION The recapitalization of Biocartis was completed last week, strengthening the balance sheet with a new investment of €40 million and a €132 million conversion of debt to equity.Product portfolio expansion with the launch of three breast cancer products: the Idylla™ PIK3CA-AKT1 Mutation Assay and, in collaboration with our partner APIS, the APIS Breast Cancer Subtyping...
Press release Biocartis NV: Biocartis Hosts Corporate Workshop and Ann...
Press release Biocartis NV: Biocartis Hosts Corporate Workshop and Announces Seven Idylla™ Abstracts to be Presented at AMP 2023 Annual Meeting PRESS RELEASE - 13 November 2023, 07:00 CET Biocartis Hosts Corporate Workshop and Announces Seven Idylla™ Abstracts to be Presented at AMP 2023 Annual Meeting Mechelen, Belgium and Itasca (IL), United States, 13 November 2023 – Biocartis, an innovative molecular diagnostics company, announces today that it will host a free corporate workshop at the Annual Meeting of the ‘Association for Molecular Pathology’ (AMP), a leading molecular diagnost...
Press release Biocartis Group NV: Announcement regarding Enforcement b...
Press release Biocartis Group NV: Announcement regarding Enforcement by Secured Creditors PRESS RELEASE REGULATED INFORMATION 31 October 2023, 15:30 CET ANNOUNCEMENT REGARDING ENFORCEMENT BY SECURED CREDITORS The Company’s Secured Creditors have enforced their security over the shares of the Biocartis operating subsidiaries Enforcement not expected to impact Biocartis's customers, suppliers, partners or employees Mechelen, Belgium, 31 October 2023 – Biocartis Group NV (the “Company”) (Euronext Brussels: BCART) announces that it has been informed by its Secured Creditors (as defined below...
Persbericht Biocartis Group NV: Mededeling betreffende uitwinning door...
Persbericht Biocartis Group NV: Mededeling betreffende uitwinning door gewaarborgde schuldeisers PERSBERICHT - GEREGULEERDE INFORMATIE - 31 oktober 2023, 15:30 CET MEDEDELING BETREFFENDE UITWINNING DOOR GEWAARBORGDE SCHULDEISERS De Secured Creditors van de onderneming hebben hun zekerheid op de aandelen van de operationele dochterondernemingen van Biocartis afgedwongenDe uitwinning zal naar verwachting geen gevolgen hebben voor de klanten, leveranciers, partners of werknemers van Biocartis Mechelen, België, 31 oktober 2023 - Biocartis Group NV (de "Vennootschap") (Euronext Brussel: BCART...
Press release Biocartis Group NV: Four Abstracts Showing Excellent Dat...
Press release Biocartis Group NV: Four Abstracts Showing Excellent Data for Idylla™ Presented at European Society of Molecular Oncology Congress (ESMO) PRESS RELEASE 20 October 2023, 07:00 CEST Four Abstracts Showing Excellent Data for Idylla™ Presented at European Society of Molecular Oncology Congress (ESMO) Mechelen, Belgium, 20 October 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company, announces that four study abstracts on Idylla™ have been selected for poster presentations at the international ESMO (European Society of Molecular On...
Persbericht Biocartis Group NV: Vier abstracts, die uitstekende result...
Persbericht Biocartis Group NV: Vier abstracts, die uitstekende resultaten voor Idylla™ tonen, worden gepresenteerd op het European Society of Molecular Oncology (ESMO) congres PERSBERICHT 20 oktober 2023, 7:00 CEST Vier abstracts, die uitstekende resultaten voor Idylla™ tonen, worden gepresenteerd op het European Society of Molecular Oncology (ESMO) congres Mechelen, België, 20 oktober 2023 - Biocartis Group NV (de 'Vennootschap' of 'Biocartis'), een innovatief bedrijf in de moleculaire diagnostiek, kondigt aan dat vier studie abstracts over Idylla™ zijn geselecteerd voor posterpresentat...
Press release Biocartis Group NV: Biocartis Honors Breast Cancer Aware...
Press release Biocartis Group NV: Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio PRESS RELEASE 16 October 2023, 7:00 CEST Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio Mechelen, Belgium, 16 October 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company, announces the launch of the new Breast Cancer Portfolio during the Breast Cancer Awareness month: the Idylla™ PIK3CA-AKT1 Mutation Assay and, in collaboration with APIS Assay Technologies (‘APIS’), the APIS Breast C...
Persbericht Biocartis Group NV: Biocartis steunt Borstkankermaand met ...
Persbericht Biocartis Group NV: Biocartis steunt Borstkankermaand met lancering van een borstkankerportfolio PERSBERICHT 16 oktober 2023, 7:00 CEST Biocartis steunt Borstkankermaand met lancering van een borstkankerportfolio Mechelen, België, 16 oktober 2023 - Biocartis Group NV (de 'Vennootschap' of 'Biocartis'), een innovatief bedrijf in de moleculaire diagnostiek, en APIS Assay Technologies Ltd. ('APIS'), een privébedrijf gebaseerd in het Verenigd Koninkrijk en gespecialiseerd in moleculaire diagnostiek, kondigen de lancering aan van een nieuw borstkankerportfolio tijdens oktober Borst...
Press release Biocartis Group NV: Biocartis Announces Expansion of its...
Press release Biocartis Group NV: Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialize the APIS ESR1 Mutations Kit PRESS RELEASE 12 October 2023, 7:00 CEST Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialize the APIS ESR1 Mutations Kit Mechelen, Belgium, 12 October 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company and APIS Assay Technologies Ltd. (‘APIS’), a private UK based company specializing in molecular diagnostics, today announced the expansion...
Persbericht Biocartis Group NV: Biocartis kondigt uitbreiding aan van ...
Persbericht Biocartis Group NV: Biocartis kondigt uitbreiding aan van de samenwerking met APIS Assay Technologies en zal de APIS ESR1 Mutations Kit commercialiseren PERSBERICHT 12 oktober 2023, 7:00 CEST Biocartis kondigt uitbreiding aan van de samenwerking met APIS Assay Technologies en zal de APIS ESR1 Mutations Kit commercialiseren Mechelen, België, 12 oktober 2023 - Biocartis Group NV (de 'Vennootschap' of 'Biocartis'), een innovatief bedrijf in de moleculaire diagnostiek, en APIS Assay Technologies Ltd. ('APIS'), een privébedrijf gebaseerd in het Verenigd Koninkrijk gespecialiseerd i...
Press Release Biocartis Group NV: Disclosure of transparency notificat...
Press Release Biocartis Group NV: Disclosure of transparency notification PRESS RELEASE: REGULATED INFORMATION 3 October 2023, 7:00 CEST Disclosure of transparency notification Mechelen, Belgium, 3 October 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading ...
Persbericht Biocartis Group NV: Openbaarmaking van transparantiekennis...
Persbericht Biocartis Group NV: Openbaarmaking van transparantiekennisgeving PERSBERICHT: GEREGLEMENTEERDE INFORMATIE3 oktober 2023, 7:00 CEST Openbaarmaking van transparantiekennisgeving Mechelen, België, 3 oktober 2023 – Biocartis Group NV (de ‘Vennootschap’ of ‘Biocartis’), een innovatief bedrijf in de moleculaire diagnostiek (Euronext Brussels: BCART), kondigt vandaag aan, overeenkomstig artikel 14, lid 1 van de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in emittenten waarvan aandelen zijn toegelaten tot de verhandeling op een gereglementeerde markt...
- Alex Cogut
Coverage update
Given team and strategy changes, Alex Cogut is now assuming coverage of Achilles Therapeutics, Adaptimmune Therapeutics, Autolus, Calliditas, Cellectis, Galapagos, GenSight, Hansa Biopharma, Heidelberg Pharma, Immunocore, Innate Pharma, Sesorion and ValerioWe drop coverage of Celyad Oncology BioNte
CLLS CELLECTIS ADS
ADAP ADAPTIMMUNE THERAPEUTICS ADS
TNG TRANSGENE SA
IPH INNATE PHARMA SA CLASS A
CYAD CELYAD ONCOLOGY
HNSA HANSA BIOPHARMA AB
SIGHT GENSIGHT BIOLOGICS SA
5142 ACHILLES CORP.
POXEL POXEL SA
BCART BIOCARTIS GROUP NV
CRSP CRISPR THERAPEUTICS AG
GNMSY GENMAB A/S
BNTX BIONTECH SE
CALTX CALLIDITAS THERAPEUTICS AB
IMCR IMMUNOCORE HOLDINGS ADS
IMTX IMMATICS
GLG GALAPAGOS
- Lynn Hautekeete
- Sharad Kumar S.P
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Press Release Biocartis Group NV: Biocartis announces H1 2023 Results ...
Press Release Biocartis Group NV: Biocartis announces H1 2023 Results and provides an update on the operational reorganization and recapitalization PRESS RELEASE: INSIDE INFORMATION / REGULATED INFORMATION 26 September 2023, 07:00 CEST BIOCARTIS ANNOUNCES H1 2023 RESULTS AND PROVIDES AN UPDATE ON THE OPERATIONAL REORGANIZATION AND RECAPITALIZATION Company will host a conference call with live webcast presentation today at 14:30 CEST / 13:30 BST (UK) / 08:30 EDT (US) to discuss H1 2023 results Solid performance with 22% growth of oncology cartridge revenue, a 40% gross margin on product ...
Persbericht Biocartis Group NV: Biocartis kondigt resultaten H1 2023 a...
Persbericht Biocartis Group NV: Biocartis kondigt resultaten H1 2023 aan en geeft een update over de operationele reorganisatie en herkapitalisatie PERSBERICHT: VOORKENNIS / GEREGLEMENTEERDE INFORMATIE 26 september 2023, 07:00 CEST BIOCARTIS KONDIGT RESULTATEN H1 2023 AAN EN GEEFT EEN UPDATE OVER DE OPERATIONELE REORGANISATIE EN HERKAPITALISATIE Bedrijf organiseert vandaag een conference call met live webcast presentatie om 14:30 CEST / 13:30 BST (VK) / 08:30 EDT (VS) om de resultaten van H1 2023 te bespreken Solide prestatie met 22% groei van inkomsten uit oncologiecartridges, een brut...
Press Release Biocartis Group NV: Agreement regarding recapitalization...
Press Release Biocartis Group NV: Agreement regarding recapitalization of operating subsidiaries by secured by secured creditors and wind down of listed holding company PRESS RELEASE:INSIDE INFORMATION / REGULATED INFORMATION 26 September 2023, 07:00 CEST AGREEMENT REGARDING RECAPITALIZATION OF OPERATING SUBSIDIARIES BY SECURED CREDITORS AND WIND DOWN OF LISTED HOLDING COMPANY The Company’s Secured Creditors (being its First Lien Creditors and Bondholders, as defined below) will take ownership of the Biocartis operating subsidiaries through enforcement and inject EUR 40 million of new eq...
Persbericht Biocartis Group NV: Overeenkomst betreffende herkapitalisa...
Persbericht Biocartis Group NV: Overeenkomst betreffende herkapitalisatie van operationele dochteronderneming door gewaarborgde schuldeisers en liquidatie van beursgenoteerde holdingmaatschappij PERSBERICHT: VOORKENNIS / GEREGULEERDE INFORMATIE 26 september 2023, 07:00 CEST OVEREENKOMST BETREFFENDE HERKAPITALISATIE VAN OPERATIONELE DOCHTERONDERNEMINGEN DOOR GEWAARBORGDE SCHULDEISERS EN LIQUIDATIE VAN BEURSGENOTEERDE HOLDINGMAATSCHAPPIJ De Secured Creditors van de Vennootschap (zijnde de First Lien Creditors en Obligatiehouders, zoals hieronder gedefinieerd) zullen eigenaar worden van de ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.